The SAR 200 million manufacturing facility will produce 1 billion tablets, 300 million capsules and 30 million bottles of syrups and suspensions per year
The state-of-the-art pharmaceutical manufacturing facility Julphar Saudi Arabia officially opened during a much-anticipated on-site ribbon-cutting ceremony, which took place in Saudi Arabia’s King Abdullah Economic City (KAEC) on April 20th in the presence of Saudi Arabia and United Arab Emirates governmental representatives and officials.
The factory was inaugurated by His Excellency Dr. Tawfiq Al-Rabiah, Minister of Health for Kingdom of Saudi Arabia with auspicious presence of dignitaries including the CEO of SFDA (Saudi Food & Drug Authority) Dr. Hisham Al Jeddaei, Secretary General of Economic Cities Authority Mr. Mohanud Abdul-Mohsin Helal, CEO of Emaar Economic City Mr. Fahd Al-Rasheed, CEO of Industrial Valley Mr. Rayan Qutub & Chairman Cigalah Group Sheikh Yasser Naghi.
During the one-day event, Julphar Saudi Arabia held a factory site tour, where media and guests had the opportunity to visit the world-class facility and see its production process.
Julphar’s Chairman, His Highness Sheikh Faisal Bin Saqr Al Qassimi, said: “I am grateful to all for their well-founded trust in Julphar and for attending today’s event. With the launch of Julphar Saudi Arabia, we are strengthening our commitment towards Julphar’s biggest market: Saudi Arabia, and its people. The medicines will be manufactured locally, which will help reduce the cost of production and ensure all our high quality products are affordable to families in the kingdom. The addition of the Julphar plant in Saudi Arabia also supports the company’s vision to expand its manufacturing presence in the region.”
“The plant will have the capacity to produce up to 1 billion tablets, 300 million capsules and 30 million bottles of syrups and suspensions per year,” added Sheikh Abdullah Bin Faisal Al Qasimi, Vice-Chairman of the Board. “Julphar Saudi Arabia also complies with international Current Good Manufacturing Practice cGMP standards. It integrates quality into all stages of manufacturing and aim for continuous improvement, which is in line with the company’s objective to ensure our people’s safety by producing high quality products through world-class facilities.”
Julphar Saudi Arabia is the result of the collaboration between MENA’s largest generic pharmaceutical company, Julphar Gulf Pharmaceutical Industries, and its local partner Cigalah Group, a leading healthcare distributor in the Saudi market.
The construction of the factory is estimated to SAR 200 million and is expected to employ Saudi talents with on-going training & development.
The 75,000 sqm. plant integrates an oral solid dosage plant and oral liquid formulation plant, which incorporate the most sophisticated processes and control systems (such as raw material transfer through closed systems, recipe management with minimal operator intervention and automated cleaning) to ensure the production of high quality products.